Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etizest-plus
- Development stage
- Unknown
- Lead developer
- Consern Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Etizest-plus is a combination pharmaceutical product manufactured by Apgar Pharmaceuticals, primarily indicated for the treatment of comorbid depression and anxiety disorders. It consists of two active small molecule ingredients: etizolam and escitalopram. Etizolam is a thienodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, providing rapid anxiolytic, sedative, and muscle relaxant effects. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting the serotonin transporter (SERT), addressing underlying depressive symptoms and providing long-term management of mood disorders. This combination is designed to offer both immediate relief of acute anxiety symptoms and sustained therapeutic benefit for neuropsychiatric conditions.
- Brand names
- Etizest-plus
- Other names
- Etizolam + Escitalopram
02
Targets
PTAFR (Platelet-activating factor receptor)SERT (Sodium-dependent serotonin transporter)BZD site (GABA-A receptor benzodiazepine site)
Beyond the preview
Go deeper on Etizest-plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etizest-plus.